CJC-1295 (DAC) 2mg

Name: CJC-1295 (DAC) 2mg
SKU: PL-2MG-PC01
Price: 39.00 USD
Availability: InStock

Brands PeptideLion

$39.00

out of stock

Sku:

PL-2MG-PC01

Brands: PeptideLion

Description

Overview:

What is CJC-1295?

CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog made up of 30 amino acids. It has been found to be highly effective with regard to the increase of growth hormone secretion and IGF-1 without negatively affecting the pulsatility of GH secretion.

CJC-1295 is often combined with Ipamorelin due to its enhanced specificity as a GHRH. This peptide generates similar increases in growth hormone secretion but without appetite stimulation and an increase in cortisol, acetylcholine, prolactin, and aldosterone seen with other peptides in its class. This peptide has been found to be very well-tolerated and perfect when combined with Ipamorelin.

CJC-1295 was further modified by adding DAC (Drug Affinity Complex) to it. DAC binds to a blood protein called albumin, which increases its half-life to 8 days. It is called CJC 1295 + DAC. CJC 1295 can also be compounded in a non-DAC form which mimics a more normal physiologic GH spike each night.

The longer half-life from the DAC binding to albumin means injections are only required once or twice per week. However, the long half-life and relatively constant blood level provide a constant stimulus for GH release from the pituitary through the GHRH receptor, which is not physiological. This can decrease the GH pulse amplitude which will result in decreased GH tissue stimulation.

Is CJC-1295 DAC same as CJC-1295?

CJC-1295 DAC and CJC-1295 (Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical, but the difference between the two peptides is the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life of up to approximately 8 days. Many scientists have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered much more natural as they produce a short pulse of Human Growth Hormone.

Scientific Information:

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. Placebo-treated GHRHKO mice and mice heterozygous for the GHRHKO allele served as controls.

GHRHKO animals receiving daily doses of CJC-1295 maintained normal body weight and length. Mice treated every 48 and 72 hours gained more body weight and length compared to placebo-treated animals, though they did not fully normalize growth. Femur and tibia lengths remained normal in animals treated every 24 and 48 hours. Relative lean mass and subcutaneous fat mass stayed normal across all treated groups. CJC-1295 increased total pituitary RNA and GH mRNA, indicating somatotroph cell proliferation, as confirmed by immunohistochemistry images. These findings show that once-daily administration of CJC-1295 can sustain normal body composition and growth in GHRHKO mice. However, the same dose proves less effective when administered every 48 or 72 hours.

How CJC-1295 Works In The Body?

CJC 1295 offers many benefits to the body, including:

Increased growth hormone secretion and IGF-1 Levels with no increase in prolactin
Increased Body Weight and Length through increased protein synthesis
Increased Muscle Growth
Increased Bone Density
Improved Immune Function
Improved Cognition and Memory
Increased Collagen Production
Increased Fat Loss
Increased Cellular Repair and Regeneration

CJC-1295 also promotes slow-wave deep sleep, which is responsible for the highest level of muscle growth memory retention, and rejuvenation.

Research Highlights:

CJC-1295 DAC is a long-acting growth hormone-releasing hormone that stimulates the anterior pituitary gland to release more growth hormone. The DAC moiety prolongs the plasma half-life of CJC-1295. The body releases GHRH in pulses, alternating with pulses of somatostatin, the growth-hormone inhibiting hormone. The peptide aims to treat visceral fat deposits in obese AIDS patients, as higher levels of exogenous HGH are thought to increase lipolysis (fat loss). Clinical research was successful for most subjects. Ghrelin, released from the gut, acts as a hunger hormone and works synergistically with GHRH, also suppressing somatostatin to facilitate the GHRH pulse.

Studies show that combining GHRP-6 with CJC-1295 DAC significantly increases GH and IGF-1 release without raising prolactin levels. Researchers designed CJC-1295 DAC as an exceptionally effective hGH secretagogue. The DAC (Drug Affinity Complex) portion extends its half-life by binding with serum albumin, which protects the peptide from degradation. This binding occurs when a lysine link attaches the DAC to a reactive chemical called maleimidoproprionic acid (MPA).

Despite the fact that there has been plenty of research on CJC-1295 + DAC in relation to how it functions and the benefits that can be derived from such functionality, it should be emphasized that the peptide is still just intended for scientific study at this point in time. Because of this, any findings or observations relating to CJC-1295 + DAC’s overall functionality, mechanics, and benefits, should exclusively be the product of the study performed in a strictly contained environment.